Alladapt touts data on food allergy drug as it preps for PhIII
Alladapt Immunotherapeutics said its food allergy drug helped children consume more of what they’re allergic to in a clinical trial, according to results presented on Sunday. Next, the Menlo Park, CA-based biotech is gearing up for a Phase III trial of its oral immunotherapy.
In a Phase I/II study with 61 children aged 4 to 17, 11 of 20 participants who received the high dose of Alladapt’s oral drug ADP101 became desensitized to 600 mg or more of protein from at least one of their allergens at 40 weeks, compared to just 4 of 20 of those who received placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
